Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RxFINE-Low: Ribociclib + Hormone Therapy vs Chemotherapy + Ribociclib + Hormone Therapy in High Anatomic Stage ER+/HER2- Breast Cancer
NCT07391774Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2026
- Primary completion
- Jul 2029
- Countries
- 2
01
Overview
A Phase 3 trial of ribociclib in breast cancer, sponsored by National Cancer Institute. Started Aug 2026; status: recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07391774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07391774.